Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Dec 28;51(2):735-742.
doi: 10.3906/sag-2008-37.

Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?

Serdar Şahin  1 , Özlem Haliloğlu  2 , Özge Polat Korkmaz  1 , Emre Durcan  1 , Hümeyra Rekalı Şahin  1 , Volkan Demirhan Yumuk  1 , Taner Damcı  1 , Hasan Mahmut İlkova  1 , Zeynep Oşar Siva  1
Affiliations
Randomized Controlled Trial

Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?

Serdar Şahin et al. Turk J Med Sci. .

Abstract

Background/aim: To evaluate the impact of treatment with sodium-glucose co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients with Type 2 diabetes mellitus (T2DM).

Materials and methods: Ninety-seven patients with type 2 diabetes admitted to tertiary care hospital diabetes clinic were included. Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects continued with their baseline treatment or were added other medications as needed (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final visit.

Results: Physical function, emotional role limitation, vitality, mental health, pain, general health perception scores of SF-36 were significantly improved in Group A, at the end of the follow-up period. There was no significant change in terms of PSQ, BAI scores, and hypoglycaemia documented in all groups. The intervention-related change in HbA1c level, body weight, and body mass index were significantly higher in Group A.

Conclusion: The QoL was improved in people with diabetes who were taking SGLT2 inhibitors. This may be explained by weight loss observed in participants.

Keywords: Anxiety; sleep quality; quality of life; sodium-glucose co-transporter 2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for- profit sectors.

References

    1. Inzucchi SE Bergenstal RM Buse JB Diamant M Ferrannini E Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care . 2015;38:140–149. - PubMed
    1. Salber GJ Wang YB Lynch JT Pasquale KM Rajan TV Metformin use in practice: compliance with guidelines for patients with diabetes and preserved renal function. Clinical Diabetes . 2017;35:154–161. - PMC - PubMed
    1. Dardi I Kouvatsos T Jabbour SA SGLT2 inhibitors. Biochemical Pharmacology . 2016;101:27–39. - PubMed
    1. Cosentino F Grant PJ Aboyans V Bailey CJ Ceriello A ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal . 2020;41:255–323. - PubMed
    1. Wiviott SD Raz I Bonaca MP Mosenzon O Kato ET The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. Heart Journal . 2018;200:83–89. - PubMed

Publication types

MeSH terms

Substances